Full-Time
Confirmed live in the last 24 hours
Develops medicines for serious diseases
$82.6k - $134.8kAnnually
Senior
Gillette, WY, USA
This role requires working onsite a minimum of 3 days per week.
You match the following Regeneron Pharmaceuticals's candidate preferences
Employers are more likely to interview you if you match these preferences:
Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its development efforts. Unlike many competitors, Regeneron focuses on both research and commercialization, generating revenue through the sale of its approved medicines and licensing its technologies. The goal of Regeneron is to improve patient outcomes by providing effective treatments and ensuring that its products meet high safety and efficacy standards.
Company Size
10,001+
Company Stage
IPO
Total Funding
$684M
Headquarters
Town of Greenburgh, New York
Founded
1988
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Wellness Program
Paid Vacation
Equity Awards
Annual Bonuses
Flexible Work Hours
Regeneron Science Talent Search Sees Record Number of Applicants; $1.2 Million to be Awarded to Nation's Most Promising Young Scientists and Their SchoolsWASHINGTON, Jan. 8, 2025 /PRNewswire/ -- Society for Science (the Society) today announced the top 300 scholars in the Regeneron Science Talent Search 2025, the nation's oldest and most prestigious science and math competition for high school seniors. The 300 scholars will be awarded $2,000 each and their schools will be awarded $2,000 for each enrolled scholar.The Regeneron Science Talent Search scholars were selected from nearly 2,500 entrants from 795 high schools across 48 states, American Samoa, Guam, Washington, D.C., Puerto Rico and 14 other countries. US citizens living abroad are eligible to apply.Scholars were chosen based on their outstanding research, leadership skills, community involvement, commitment to academics, creativity in asking scientific questions and exceptional promise as STEM leaders demonstrated through the submission of their original, independent research projects, essays and recommendations. The 300 scholars hail from 200 American and international high schools in 33 states, Washington D.C., China, Hong Kong, Malaysia, and Switzerland.The full list of scholars can be viewed here: https://www.societyforscience.org/regeneron-sts/2025-scholars/"Congratulations to the 300 scholars in this year's Regeneron Science Talent Search," said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. "With a record-breaking number of applications, these exceptional young scientists and engineers represent the best in the nation
Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of 13.4% from 2023 to 2033. With a valuation of USD 235 billion in 2023, the market is expected to surpass USD 824 billion by the end of the forecast period, driven by advancements in monoclonal antibody therapies and increasing demand for targeted treatments.The growing preference for protein-based, non-chemical treatments has fueled the adoption of monoclonal antibody therapy, particularly for cancer and cell-based diseases. Enhanced research and development efforts, supported by government funding, are further strengthening the effectiveness and accessibility of these treatments. Additionally, the expansion of cancer-specialized hospitals is boosting demand for antibody therapies.The market saw a significant boost during the COVID-19 pandemic, with the FDA approving advanced antibody therapies for treatment, leading to an accelerated CAGR of 18.2% between 2017 and 2022. As immunotherapy and chemotherapy resistance challenges continue, monoclonal antibodies have emerged as a promising alternative due to their high efficacy and reduced side effects.Request a Sample Report Now to get Premium Insights: https://www.futuremarketinsights.com/report-sample#5245502d47422d3134333632Key Takeaways:The antibody therapy market is set to grow from USD 235 billion in 2023 to USD 824 billion by 2033 at a CAGR of 13.4%.Rising cancer prevalence, regulatory approvals, and R&D collaborations are key growth drivers.Monoclonal antibodies offer a promising alternative to traditional chemotherapy, addressing tumor resistance and reducing side effects.Increased demand for targeted therapies and expanded healthcare infrastructure are expected to fuel long-term market growth.Key Growth DriversIncreasing Prevalence of Chronic Diseases The rising incidence of chronic diseases, particularly cancer and autoimmune disorders, is a significant driver for the antibody therapy market. As these conditions become more prevalent, the demand for effective treatment options, such as monoclonal antibodies, increases
REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP announces that Regeneron Pharmaceuticals, Inc. investors with substantial losses have opportunity to lead Class Action lawsuit.
To kick off the project, Regeneron made an upfront strategic investment of $119.5 million into Truveta, while Illumina chipped in $20 million as part of a series C financing.
The Regeneron Science Talent Search Celebrates and Rewards Today's Most Talented Young Minds Driving Innovation and Progress through Scientific ExplorationTARRYTOWN, N.Y. and WASHINGTON, Jan. 23, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in the 2025 Regeneron Science Talent Search (STS), the U.S.'s longest-running and most distinguished science, technology, engineering and math (STEM) competition for high school seniors
ATTENTION NASDAQ: REGN INVESTORS: contact Berger Montague about a Regeneron pharmaceuticals, inc. class action lawsuit.
Seattle-based health data company Truveta secured $320 million in funding to launch the Truveta Genome Project, aiming to create the largest and most diverse genomic dataset. The investment, from 17 health systems, Illumina, and Regeneron, elevates Truveta's valuation to over $1 billion. Regeneron will sequence exomes of 10 million volunteers. Truveta's total funding is nearly $500 million, with Microsoft as the exclusive cloud provider for the project.
Erste Asset Management GmbH makes new $42.48 million investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Oxular is working on the development of novel drug/device combinations for sight-threatening retinal disorders, which is a key area of focus for Regeneron.
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistaminesFDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decadeParis and Tarrytown, NY, November 15, 2024. The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment. The target action date for the FDA decision is April 18, 2025.The resubmitted sBLA is supported by data from the multi-study LIBERTY-CUPID phase 3 clinical program (Study A, Study B, and Study C) for Dupixent in CSU. The sBLA adds results from Study C, which was conducted in patients with uncontrolled CSU who were on standard-of-care antihistamines. Study C, the second LIBERTY-CUPID pivotal study in biologic-naïve patients, met its primary and key secondary endpoints, confirming results seen in the previous Study A. Results showed Dupixent significantly reduced itch and urticaria activity (itch and hives).Safety results in all LIBERTY-CUPID phase 3 studies were generally consistent with the known safety profile of Dupixent in its approved indications
Tezspire met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps. Tezspire demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo. Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen’s Tezspire (tezepelumab) demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo